Multiomics is about capturing the multiple biological layers, DNA, RNA, and more that together shape health and disease. We view AI as a lynchpin reinforcing a powerful flywheel of innovation across multiomics as biological data scales, models improve, and in turn enabling better therapeutics, tools, and diagnostics. In effect, a virtuous cycle.The cost collapse for biological data is striking. The first human reference genome took more than a decade and nearly $3 billion to produce. That was about 25 years ...

ARK's Multiomics Research Analysts, Shea Wihlborg, takes us through the Multiomics section of ARK's Big Ideas 2026 report. To learn more, download the full report at: https://www.ark-invest.com/big-ideas-2026 ...

Summary of Guardant Health Conference Call Company Overview - **Company**: Guardant Health - **Industry**: Life Sciences Tools and Diagnostics Key Points Business Drivers and Growth Opportunities - Guardant Health has three major business drivers: treatment selection, minimal residual disease (MRD), and screening, all contributing to hypergrowth opportunities [4][5][6] - The SERENA-6 trial is a significant growth driver for Guardant360, focusing on liquid biopsy for treatment selection in breast cancer patients [4][9] - The FDA approval for the ESR1 mutation detection is anticipated in the first half of the year, which could double the volume of breast cancer testing [5][9] Clinical Utility and Testing - The ESR1 mutation is a mechanism of resistance in breast cancer, and its detection can influence treatment decisions [5][6] - Guardant360 is set to become the first monitoring companion diagnostic (CDx) for liquid biopsy, expanding its utility beyond single time-point testing [10][12] - The company has seen a significant increase in testing volume post-FDA approvals, which enhances conversations with commercial payers regarding reimbursement [12][14] Product Development and Technology - Guardant Health is leveraging a large database of genomic and epigenomic data to enhance its product offerings, including the development of Smart Apps for clinical information [13][14] - The Reveal product is the fastest-growing test in the portfolio, with expectations for continued growth in both adjuvant and surveillance settings [16][19] - The Reveal Ultra launch is anticipated later this year, with the potential for significant market impact, although it is not included in the 2026 revenue guidance due to uncertainties [35][36] Market Strategy and Adoption - The Shield product targets unscreened patient populations, with 90% of tested patients having not been screened in the last five years, indicating a substantial market opportunity [42][52] - Guardant Health is focusing on increasing productivity among existing sales representatives and expanding its sales force to drive growth [43][46] - The company is not yet competing directly with stool-based tests but is seeing some incidental use cases where patients prefer blood tests over traditional methods [52] Reimbursement and Financial Outlook - Current reimbursement for CRC surveillance is approximately $1,644, with expectations for similar levels for new products [36][37] - The company is optimistic about future reimbursement discussions as it continues to engage with commercial payers [12][37] Future Opportunities - There is potential for future advancements in MRD testing, including the ability to locate and characterize residual disease through the same test [24][32] - Guardant Health is exploring the integration of multi-omics data to enhance its diagnostic capabilities [13][14] Additional Insights - The company is strategically positioning itself to fill care gaps in cancer screening, particularly among populations that have not previously engaged with screening technologies [42][52] - Guardant Health's approach to direct-to-consumer (DTC) marketing is evolving, with a focus on educating consumers about the importance of screening [53][54]

Core Insights - Illumina's shares have increased by 44.8% over the past year, significantly outperforming the industry and S&P 500 [1][9] - The company is focused on long-term growth through its core sequencing business, multiomics expansion, and enhanced services, data, and software capabilities [2][4] Company Performance - Illumina's core sequencing business is experiencing growth, particularly with the NovaSeq X platform, which has driven a 7% increase in ex-China revenues in Q4 [4][9] - The company achieved its second-highest quarterly placements of NovaSeq X since its launch in 2023 [5] Strategic Initiatives - Illumina is expanding into multiomics through acquisitions, such as SomaLogic, and has launched the Illumina Connected Multiomics platform [6] - The introduction of the BioInsight business and the Billion Cell Atlas data product has garnered strong interest from biopharma partners [7] Financial Health - Non-GAAP gross margins improved by 165 basis points, and non-GAAP operating margins expanded by 400 basis points year-over-year [10] - As of the end of Q4, Illumina had cash and short-term investments totaling $1.63 billion, with $500 million in short-term debt, indicating a strong liquidity position [10] Market Challenges - In March 2025, China imposed a ban on imports of Illumina's NGS sequencers, which poses a significant challenge in a market with high sequencing demand [11] - The company is also facing macroeconomic pressures, including inflation and currency fluctuations [11] Future Projections - The Zacks Consensus Estimate predicts a 6.2% increase in EPS for 2026 and a 14.8% increase for 2027, with revenues expected to grow to $4.54 billion in 2026 and $4.83 billion in 2027 [12]

Core Insights - BostonGene and Unilever have formed a strategic partnership to leverage AI and multiomics research for consumer innovation, aiming to inspire the next generation of science-based product development [1] - The collaboration will utilize BostonGene's advanced AI capabilities and omnimodal data integration alongside Unilever's scientific expertise to explore biological differences and generate actionable insights for product innovation [1] Company Overview - BostonGene specializes in AI-driven solutions for tumor and immune biology, integrating genomic, transcriptomic, and immune data with clinical outcomes to enhance drug development and patient care [1] - Unilever is a leading global supplier of consumer goods, with sales of €50.5 billion in 2025 and products used by 3.7 billion people daily [1] Partnership Objectives - The partnership aims to apply advanced AI and multiomics approaches to uncover insights that will drive innovative product development for Unilever's consumer base [1] - Unilever's investment in cutting-edge science and technology is intended to maintain its competitive edge in scientific innovation [1] Future Implications - The collaboration is expected to extend BostonGene's foundation model beyond oncology into broader areas of human biology, potentially accelerating discoveries that influence consumer-focused science [1]

Core Insights - Illumina has announced significant breakthroughs in oncology through the use of its multiomics solutions, including spatial transcriptomics, 5-base sequencing, and proteomics technologies, which enhance precision diagnostics and targeted therapeutics development [1][2] Group 1: Multiomics Solutions - The integration of multiple omic insights provides unprecedented biological depth, enabling researchers to achieve breakthroughs in oncology and pharmacogenomics [1] - Illumina's Connected Multiomics platform streamlines multimodal data analysis, facilitating a deeper understanding of tumor microenvironments [1] Group 2: Spatial Technology - Illumina Spatial Technology has been utilized to decode complex tissues, such as the human lymphatic system, improving cancer diagnosis and prognosis [1] - Research using Illumina Spatial Technology has produced the first whole transcriptome spatial datasets for human lymphatic collector vessels, aiding in the understanding of lymphatic vessel functions [1] Group 3: 5-Base Sequencing - The 5-base solution has been applied in pediatric kidney cancer research, allowing for simultaneous genomic and methylation profiling, which enhances diagnostic accuracy [1][2] - This solution has successfully identified cases of rhabdoid tumors that were missed by conventional genomic methods, indicating its potential for improving patient outcomes [1] Group 4: Ovarian Cancer Research - Illumina's technologies have enabled researchers to differentiate between cancerous and benign tumor types in ovarian cancer, creating a multiomic framework for future research [2] - The combination of 5-base sequencing and Illumina Protein Prep has led to the identification of novel gene sets and pathways in ovarian cancer, opening new avenues for biomarker and drug development [2] Group 5: Advancements in Diagnostics - The integration of multiomics analytics provides deeper insights into cancer mechanisms and tumor heterogeneity, which can lead to the identification of new therapeutic targets [2] - Illumina's Connected Multiomics accelerates the sample-to-answer pipeline, overcoming challenges associated with isolated assays [2]

Hi, welcome to Arc Invest's Big Ideas 2026 deep dive. I'm Brett Winton, the chief futurist, and I'm going to start right on slide four, which is titled the great acceleration. The um the core thesis both in this section and across the entire deck is that AI is the central dynamo, the spinning wheel of magic that is accelerating you know all the five major innovation platforms that we focus on and igniting a new era of um macroeconomic growth.Um so the five major innovation platforms AI, public blockchains, ...

Join us as the ARK team takes a deep dive into our Big Ideas 2026 research report. To follow along, make sure to download the full report at https://www.ark-invest.com/big-ideas-2026 Key Sections: 00:00:00 The Great Acceleration 00:16:13 AI Infrastructure 00:27:56 The AI Consumer Operating System 00:38:23 AI Productivity 00:43:18 Bitcoin 00:55:29 Tokenized Assets 01:00:23 Decentralized Finance Applications 01:04:40 Multiomics 01:18:06 Reusable Rockets 01:22:45 Robotics 01:32:54 Distributed Energy 01:37:47 A ...

Q4 2025 Earnings Presentation February 5, 2026 © 2026 Illumina, Inc. All rights reserved. Cautionary Notes Year-over-year (YoY) denotes a comparison against the same quarter of the previous fiscal year, while quarter-over-quarter (QoQ) or "sequential" denotes a comparison against the previous fiscal quarter. In addition, all references to China refer to our Greater China Region, which also includes Taiwan and Hong Kong. © 2026 Illumina, Inc. All rights reserved. 2 RGB: 229, 96, 0 RGB: 228, 189, 255 RGB: 255 ...

Core Insights - Illumina has completed the acquisition of SomaLogic, enhancing its capabilities in proteomics and multiomics, which will facilitate faster drug discovery and improve healthcare outcomes [1][2][5] Group 1: Acquisition Details - The acquisition was finalized for $350 million in cash, with potential additional payments of up to $75 million based on performance milestones [6] - This acquisition builds on a prior partnership that began in late 2021, aimed at integrating SomaLogic's technology with Illumina's high-throughput NGS platforms [5] Group 2: Strategic Implications - The combination of SomaLogic's proteomics technology with Illumina's existing innovations is expected to provide scalable insights across genomics and proteomics, enhancing customer outcomes [2][3] - Illumina aims to leverage this acquisition to strengthen its position in the growing proteomics market, thereby complementing its high-throughput sequencing business [3] Group 3: Product Integration and Support - Illumina will ensure continuity of products and services as SomaLogic's portfolio is integrated into its offerings, maintaining support for existing customers [4][5] - The integration will allow customers to generate rich multiomic datasets, utilizing a combination of SomaLogic's and Illumina's technologies [2][5]